Cytek Biosciences, Inc. (CTKB)
Cytek Biosciences, Inc. (CTKB) Q4 2024 Earnings Conference Call Transcript
Cytek Biosciences, Inc. (NASDAQ:CTKB ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Paul Goodson - IR Wenbin Jiang - CEO William McCombe - CFO Conference Call Participants David Westenberg - Piper Sandler Matthew Sykes - Goldman Sachs Chad Wiatrowski - TD Cowen Harrison Parsons - Stephens Inc. Operator Thank you for standing by, and good day, everyone. My name is RG, and I will be your conference operator today.
Cytek Biosciences, Inc. (CTKB) Tops Q4 Earnings Estimates
Cytek Biosciences, Inc. (CTKB) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.07 per share a year ago.
Upgrading Cytek Biosciences Stock On An Upcoming Catalyst
I'm upgrading Cytek Biosciences from "Hold" to "Buy" due to improving financials, expanding installed base, and strong demand for Aurora and Northern Lights systems. Cytek's Q3 FY2024 revenue up 7% YoY, driven by international demand; service revenue surged 25% YoY, boosting recurring revenue streams. The recently announced buyback plan went unnoticed, based on the EPS estimates revisions.
Cytek Biosciences, Inc. (CTKB) Q3 2024 Earnings Call Transcript
Cytek Biosciences, Inc. (NASDAQ:CTKB ) Q3 2024 Earnings Conference Call November 5, 2024 4:30 PM ET Company Participants Paul Goodson - Investor Relations Wenbin Jiang - Chief Executive Officer William McCombe - Chief Financial Officer Conference Call Participants Tejas Savant - Morgan Stanley Brendan Smith - TD Cowen Mason Carrico - Stephens John Barnidge - Piper Sandler Andrew Cooper - Raymond James Operator Thank you for standing by. At this time, I'd like to welcome everyone to the Cytek Biosciences' Third Quarter 2024 Earnings Conference Call.
Cytek Biosciences, Inc. (CTKB) Q3 Earnings and Revenues Beat Estimates
Cytek Biosciences, Inc. (CTKB) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to earnings of $0.01 per share a year ago.
Cytek Biosciences, Inc. (CTKB) Q2 2024 Earnings Call Transcript
Cytek Biosciences, Inc. (NASDAQ:CTKB ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Paul Goodson - Investor Relations Wenbin Jiang - Chief Executive Officer William McCombe - Chief Financial Officer Conference Call Participants Operator Thank you for standing by. My name is Luella, and I will be your conference operator today.
Cytek Biosciences, Inc. (CTKB) Reports Q2 Loss, Lags Revenue Estimates
Cytek Biosciences, Inc. (CTKB) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to earnings of $0.01 per share a year ago.
Cytek Biosciences (CTKB) Moves 5.1% Higher: Will This Strength Last?
Cytek Biosciences (CTKB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
